Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 2Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 101Glioblastoma 85Glioma 58Central Nervous System Neoplasms 34Astrocytoma 27Neuroblastoma 26Gliosarcoma 19Breast Neoplasms 19Neoplasms 18Oligodendroglioma 17Recurrence 14Neoplasm Metastasis 13Medulloblastoma 12Ependymoma 11Carcinoma, Non-Small-Cell Lung 11Lymphoma 9Sarcoma 8Osteosarcoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Neuroma, Acoustic 7Meningioma 7Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 7Lung Neoplasms 7Hodgkin Disease 7Burkitt Lymphoma 7Wilms Tumor 6Sezary Syndrome 6Neuroectodermal Tumors, Primitive 6Mycosis Fungoides 6

Interventions

XENP 1595 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neurodegenerative Diseases × CNS × Clear all
NCT05321498 2023-09-28

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Inmune Bio, Inc.

Phase 2 Withdrawn
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡